Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142495 | 0.82 | KDM1A (0.38) | KDM1ANPBWR1TP53MAPTLMNA | |
| SCHEMBL4142491 | 0.82 | KDM1A (0.38) | KDM1ANPBWR1TP53MAPTLMNA | |
| SCHEMBL30171196 | 0.80 | MAPT (0.54) | KDM1ANPBWR1TP53MAPTLMNA | |
| SCHEMBL20557865 | 0.79 | ELANE (0.39) | PREP | |
| SCHEMBL4146294 | 0.78 | ELANE (0.40) | MAPTPREPALDH1A1 | |
| SCHEMBL23881422 | 0.76 | KDM1A (0.44) | KDM1ATP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL19358333 | 0.76 | KDM1A (0.44) | KDM1ATP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL6837344 | 0.75 | NPBWR1 (0.53) | NPBWR1MAPTMCHR1ALDH1A1 | |
| SCHEMBL5187989 | 0.75 | PLK1 (0.43) | MAPTSMN1; SMN2 | |
| SCHEMBL20557386 | 0.74 | ELANE (0.35) | SMN1; SMN2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2009-01-15 | — | — | US | disclosed |
| US-7439253-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | NOVEXEL (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1569935-B1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | GAA, ALPI, GANAB | KDM1A 1633/4885NPBWR1 4200/4885TP53 4654/4885 |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | GAA, GANAB, ALPI | KDM1A 1962/4885NPBWR1 4240/4885TP53 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.